Idalopirdine – a small molecule antagonist of 5-HT6 with therapeutic potential against obesity

Metabolic Brain Disease

Volumn 30, Issue 6, 2015, Pages 1487-1494

  Dudek, Magdalena ^a   Marcinkowska, Monika ^a   Bucki, Adam ^a   Olczyk, Adrian ^b   Kołaczkowski, Marcin ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b SILESIAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

5 HT6 receptor antagonist; Anorectic activity; Idalopirdine; LuAE58054; Obesity; Rats with diet induced obesity

Indexed keywords

ANOREXIGENIC AGENT; ANTIOBESITY AGENT; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IDALOPIRDINE; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SEROTONIN 6 RECEPTOR; TRIACYLGLYCEROL; (2-(6-FLUORO-1H-INDOL-3-YL)-ETHYL)-(3-(2,2,3,3-TETRAFLUOROPROPOXY)BENZYL)AMINE; BENZYLAMINE DERIVATIVE; GLUCOSE BLOOD LEVEL; INDOLE DERIVATIVE; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET INDUCED OBESITY; FAT CONTENT; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; LIPID BLOOD LEVEL; LIPID DIET; LOCOMOTION; MALE; MORNING DOSAGE; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT REDUCTION; ANALYSIS; ANIMAL; ANIMAL FOOD; DRINKING; DRUG EFFECTS; EATING; LIPID METABOLISM; METABOLISM; MOTOR ACTIVITY; OBESITY; PATHOLOGY;

ADIPOSE TISSUE; ANIMAL FEED; ANIMALS; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; BENZYLAMINES; BLOOD GLUCOSE; BODY WEIGHT; DIET, HIGH-FAT; DRINKING; EATING; INDOLES; LIPID METABOLISM; MOTOR ACTIVITY; OBESITY; RATS; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 84947029366     PISSN: 08857490     EISSN: 15737365     Source Type: Journal    
DOI: 10.1007/s11011-015-9736-3     Document Type: Article

References (27)

1. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW et al (2010) LuAE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 13:1021–1033
2. Brown M, Bing C, King P, Pickavance L, Heal D, Wilding J (2001) Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. Br J Pharmacol 132:1898–1904
3. Caldirola P (2003) 5-HT6 receptor antagonism. A novel mechanism for the management of obesity. SMI Inaugural Conference on Obesity and Related Disorders, London
4. Choi S, Blake V, Cole S, Fernstrom JD (2006) Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression. Brain Res 1087:83–86
5. Clissold KA, Choi E, Pratt WE (2013) Serotonin 1A, 1B and 7 receptors of the rat medial nucleus accumbens differentially regulate feeding, water intake, and locomotor activity. Pharmacol Biochem Behav 112:1–17
6. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ (1999) Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 126:1487–1495
7. Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Mercé R et al (2006) Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 148:973–983
8. Frassetto A, Zhang J, Lao JZ, White A, Metzger JM, Fong TM et al (2008) Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5-HT6 receptor. Brain Res 1236:140–144
9. Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A et al (2010) The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 636(1–3):88–95
10. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H (2008) Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 117:207–231
11. Hilas O, Avena-Woods C (2014) Potential role of mirtazapine in underweight older adults. Consult Pharm 29:124–130
12. Jastrzębska-Więsek M, Siwek A, Kazek G, Nawieśniak B, Partyka A, Marcinkowska M et al (2013) Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacol Rep 65:998–1005
13. Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P (2005) The Cb1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567–1569
14. Liu YL, Connoley IP, Wilson CA, Stock MJ (2005) Effects of the cannabinoid Cb1 receptor antagonist Sr141716 on oxygen consumption and Soleus muscle glucose uptake in Lep(Ob)/ Lep(Ob) mice. Int J Obes 29:183–187
15. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 286:1195–1200
16. Muckelbauer R, Sarganas G, Gruneis A, Muller-Nordhorn J (2013) Association between water consumption and body weight outcomes a systematic review. Am J Clin Nutr 98:282–299
17. Pasternak A, Szymonifka MJ (2009) Tryptamine sulfonamides as 5-ht6 antagonists. WO2009073118 A1
18. Pi-Sunyer X (2002) The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 10:97S–104S
19. Pratt WE, Connolly ME (2010) Contrasting effects of systemic and central sibutramine administration on the intake of a palatable diet in the rat. Neurosci Lett 484:30–34
20. Sargent BJ, Henderson AJ (2011) Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol 1:52–58
21. Skill MJ, Dickinson K, Jones RB, Heal DJ (2000) Thermogenic effect of chronic sibutramine treatment in female Wistar rats. Int J Obes 24(1):S135
22. Wesołowska A, Nikiforuk A, Stachowicz K (2007) Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol 18:439–446
23. Wilkinson D, Wildfeld K, Colding-Jorgensen E (2014) Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer’s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 13:1092–1099
24. Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC (2001) A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41:210–219
25. World Obesity Federation (2014) http://www.worldobesity.org/aboutobesity/. Accessed 30 September 2014
26. Yanovski SZ, Yanovski JA (2014) Long-term drug treatment for obesity a systematic and clinical review. JAMA 311(1):74–86
27. Zięba R (2007) Obesity: a review of currently used antiobesity drugs and new compounds in clinical development. Postepy Hig Med Dosw 61:612–626